AI Engines For more Details: Perplexity Kagi Labs You
Irregular Heartbeat (Arrhythmias): Amiodarone is used to treat various types of arrhythmias, including ventricular arrhythmias (such as ventricular tachycardia and ventricular fibrillation) and atrial arrhythmias (such as atrial fibrillation and atrial flutter). It works by stabilizing the heart's electrical activity and slowing down abnormal rhythms.
Antiarrhythmic Effects: Amiodarone exerts its antiarrhythmic effects through multiple mechanisms, including blocking potassium channels, sodium channels, and calcium channels in cardiac cells. This helps prolong the duration of the action potential and refractory period, thereby preventing the initiation and propagation of abnormal electrical impulses in the heart.
Conversion of Atrial Fibrillation: Amiodarone may be used to convert atrial fibrillation to normal sinus rhythm in certain patients. It is often used in cases where other antiarrhythmic medications have been ineffective or contraindicated.
Maintenance Therapy: In addition to acute treatment of arrhythmias, amiodarone may be used as long-term maintenance therapy to prevent recurrence of arrhythmias and to help maintain normal heart rhythm.
Side Effects: Amiodarone can cause a wide range of side effects, some of which can be serious or potentially life-threatening. Common side effects may include fatigue, nausea, vomiting, constipation, loss of appetite, tremors, and dizziness. More serious side effects may include pulmonary toxicity, thyroid dysfunction, liver toxicity, and corneal deposits.
Pulmonary Toxicity: Amiodarone can cause pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Patients taking amiodarone should be monitored for symptoms such as cough, dyspnea, fever, and chest pain, which may indicate the development of pulmonary toxicity.
Thyroid Dysfunction: Amiodarone can affect thyroid function, leading to either hypothyroidism or hyperthyroidism. Regular monitoring of thyroid function tests is recommended in patients taking amiodarone, particularly during the first several months of treatment.
Liver Toxicity: Amiodarone may cause liver toxicity, including elevation of liver enzymes and, rarely, acute liver failure. Liver function tests should be monitored regularly during treatment with amiodarone.
Drug Interactions: Amiodarone can interact with a wide range of medications, including other antiarrhythmic drugs, anticoagulants, beta-blockers, calcium channel blockers, and statins. These interactions can affect the metabolism and efficacy of both amiodarone and the interacting drugs, potentially leading to adverse effects or reduced effectiveness.
Skin Effects: Amiodarone can cause photosensitivity reactions, blue-gray discoloration of the skin (known as "smurf syndrome"), and other dermatologic effects. Patients should avoid excessive sun exposure and use sunscreen while taking amiodarone.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 1 | 1 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.6 | 0.6 | 5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.4 | 0.17 |
| Allergies | 5.2 | 2.9 | 0.79 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 3.7 | 7.1 | -0.92 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.3 | 7 |
| Ankylosing spondylitis | 3.4 | 1.5 | 1.27 |
| Anorexia Nervosa | 1.6 | 2.9 | -0.81 |
| Antiphospholipid syndrome (APS) | 1.6 | 0.3 | 4.33 |
| Asthma | 4.1 | 2 | 1.05 |
| Atherosclerosis | 1.8 | 1.3 | 0.38 |
| Atrial fibrillation | 3.8 | 2.5 | 0.52 |
| Autism | 8.9 | 8.7 | 0.02 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 1.8 | 1.4 | 0.29 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 3.4 | -3.4 | |
| Carcinoma | 3.2 | 2.3 | 0.39 |
| Celiac Disease | 2.4 | 3.2 | -0.33 |
| Cerebral Palsy | 1.1 | 1.3 | -0.18 |
| Chronic Fatigue Syndrome | 4 | 6.8 | -0.7 |
| Chronic Kidney Disease | 4.3 | 2.9 | 0.48 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.4 | 0 |
| Chronic Urticaria (Hives) | 0.5 | 1.2 | -1.4 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.1 | 1.3 | 1.38 |
| Colorectal Cancer | 5.1 | 2.2 | 1.32 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 2.5 | -0.39 |
| COVID-19 | 7.6 | 11.4 | -0.5 |
| Crohn's Disease | 6.9 | 5.2 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 0.9 | 1.4 | -0.56 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 10.5 | 9 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.1 | 2.1 | -0.91 |
| Endometriosis | 2.3 | 1.4 | 0.64 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 2.5 | 1.7 | 0.47 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 3.1 | 2.3 | 0.35 |
| Functional constipation / chronic idiopathic constipation | 4.8 | 4.9 | -0.02 |
| gallstone disease (gsd) | 2.8 | 0.8 | 2.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 1.2 | 0 |
| Generalized anxiety disorder | 1.9 | 2 | -0.05 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.5 | 0.5 | 2 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 1.6 | -0.78 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 3.3 | 1.8 | 0.83 |
| Heart Failure | 3.6 | 1.9 | 0.89 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.1 | 1.1 | -10 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.1 | 6.1 | -0.49 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 2.4 | 0.3 | 7 |
| IgA nephropathy (IgAN) | 1.6 | 3.8 | -1.37 |
| Inflammatory Bowel Disease | 6 | 9.5 | -0.58 |
| Insomnia | 1.7 | 2.1 | -0.24 |
| Intelligence | 1.1 | 0.6 | 0.83 |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 6.3 | 4.1 | 0.54 |
| ischemic stroke | 2.3 | 1.1 | 1.09 |
| Liver Cirrhosis | 5.5 | 3.1 | 0.77 |
| Long COVID | 6.4 | 8.3 | -0.3 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1 | -0.11 |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 1.5 | 2.4 | -0.6 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.5 | 0.5 | 2 |
| Metabolic Syndrome | 7.2 | 7.3 | -0.01 |
| Mood Disorders | 9.8 | 7.5 | 0.31 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.1 | 3 |
| Multiple Sclerosis | 6.1 | 7 | -0.15 |
| Multiple system atrophy (MSA) | 1.3 | 0.7 | 0.86 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.5 | -7.33 |
| Neuropathy (all types) | 0.7 | 1 | -0.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 4.5 | -0.25 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 8.8 | 7.2 | 0.22 |
| obsessive-compulsive disorder | 4.6 | 4 | 0.15 |
| Osteoarthritis | 1.9 | 1.2 | 0.58 |
| Osteoporosis | 1.6 | 1.3 | 0.23 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 6.9 | 6 | 0.15 |
| Polycystic ovary syndrome | 7 | 2.9 | 1.41 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.1 | -0.22 |
| Primary sclerosing cholangitis | 1.9 | 3.2 | -0.68 |
| Psoriasis | 3 | 3.4 | -0.13 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.9 | 3.8 | 1.08 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 5.5 | 2.8 | 0.96 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 1.5 | 2.9 | -0.93 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.6 | 0.83 |
| Stress / posttraumatic stress disorder | 2.3 | 2.3 | 0 |
| Systemic Lupus Erythematosus | 3.4 | 1.6 | 1.13 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3 | 4.4 | -0.47 |
| Type 2 Diabetes | 8.2 | 6.5 | 0.26 |
| Ulcerative colitis | 4.4 | 6.6 | -0.5 |
| Unhealthy Ageing | 5.6 | 2.2 | 1.55 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
